Prostate Cancer

New prostate cancer research shows that adding an interim scan during therapy can help guide a patient's treatment. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging of patients with metastatic castration-resistant prostate cancer after two cycles of lutetium-177 (177Lu)-PSMA radioligand therapy has shown a significant predictive value for patient survival. The research was presented at the 2019 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). According to the National Cancer Institute, currently the five-year survival rate for men with metastatic prostate cancer is 30.5 percent. Early assessment of treatment effectiveness is essential to providing optimal care. In phase 2 trials, 177Lu-PSMA therapy has shown promising results in treating patients with metastatic castration-resistant prostate cancer. The therapy typically involves a preliminary PSMA PET scan to identify patients who are eligible for the treatmen...

MONDAY, June 24, 2019 (HealthDay News) -- A possible link between World Trade Center dust and prostate cancer in first responders has been found by researchers. Exposure to dust at the New York City site after the Sept. 11, 2001, terrorist attacks triggered chronic inflammation in the responders' prostates, which may have contributed to their cancer, according to the Mount Sinai Health researchers. They noted that inflammation has long been considered an important factor in prostate cancer. "Several years ago, I saw a first responder in his 40s who began having symptoms of prostatitis, a painful condition that involves inflammation of the prostate, soon after exposure to the World Trade Center dust," said researcher Dr. William Oh, chief of the division of hematology and medical oncology at Mount Sinai's Icahn School of Medicine. "He ultimately developed a high-grade prostate cancer several years later. It suggested to me that there might be a link between h...